Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.

Author: AsnisGregory M, BoseAnjana, ChenChangzheng, GommollCarl P, GreenbergWilliam M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Levomilnacipran sustained release demonstrated significant improvement in depressive symptoms and functioning relative to placebo. It was generally well tolerated.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: This phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and tolerability of fixed-dose levomilnacipran sustained release (SR) compared with placebo in patients with major depressive disorder (MDD); the study was conducted from September 2009-May 2011. METH...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.4088/JCP.12m08197

データ提供：米国国立医学図書館（NLM）

Evaluating the Efficacy and Safety of Levomilnacipran Sustained Release for Major Depressive Disorder

This study explores the effectiveness and safety of [treatment method] for major depressive disorder (MDD). It's a journey into the desert of [research field], where we seek to understand the potential benefits and risks of this treatment. The researchers conducted a [study type] to compare the effects of [treatment method] at different doses to a placebo. They found that [treatment method] was significantly more effective than placebo in reducing depressive symptoms and improving functioning. The study also reported that [treatment method] was generally well-tolerated, with the most common side effects being [key side effects].

A Promising Treatment Option for MDD

The study's findings offer hope for individuals struggling with MDD. [Treatment method] demonstrated significant improvement in depressive symptoms and functioning, suggesting that it could be a valuable treatment option for many patients. The researchers found that [key findings], highlighting the potential benefits of this medication for individuals seeking relief from MDD.

Navigating the Desert of Depression

This study emphasizes the importance of careful consideration and personalized care when treating MDD. While [treatment method] shows promise, it's crucial to weigh the potential benefits against the risks and side effects. The study encourages open communication between patients and healthcare providers to ensure that the most appropriate treatment plan is selected. This research reminds us that the journey through the desert of depression can be a long and difficult one, and finding the right treatment can make a world of difference.

Dr.Camel's Conclusion

This study offers a beacon of hope in the vast desert of MDD. [Treatment method] shows promise as a treatment option, offering potential relief for many individuals struggling with this debilitating condition. However, the journey through the desert of depression is unique for everyone. We must continue to seek innovative treatments and personalized care to ensure that everyone has access to the support they need to thrive.

Date :
  1. Date Completed 2013-05-30
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

23561229

DOI: Digital Object Identifier

10.4088/JCP.12m08197

Related Literature

Article Analysis
・Effects of levomilnacipran
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.